Search Tag: STEP-HFpEF

2024 30 May

  Recent research presented at Heart Failure 2024 highlights that semaglutide reduces the necessity for loop diuretics and their dosage while also positively impacting symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF), irrespective of their diuretic regimen. HFpEF occurs when the...Read more

2023 25 Aug

  In recent breakthrough research presented during a Hot Line session at ESC Congress 2023, semaglutide's effectiveness in improving symptoms and physical function related to heart failure and inducing greater weight loss was reported.   Nearly 50% of heart failure patients are affected by heart failure with preserved ejection fraction (HFpEF)....Read more